Drugs and Medications (USEF)

THE USE OF ANABOLIC STERIODS

4. Restrictions concerning the nonsteroidal anti-inflammatory drugs are as follows:

a. The maximum permitted plasma concentration of diclofenac is 0.005 micrograms per milliliter.

b. The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.

c. The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.

d. The maximum permitted plasma concentration of ketoprofen is 0.250 micrograms per milliliter.

e. The maximum permitted plasma concentration of meclofenamic acid is 2.5 micrograms per milliliter.

f. The maximum permitted plasma concentration of naproxen is 40.0 micrograms per milliliter.

g. The maximum permitted plasma concentration of firocoxib is 0.240 micrograms per milliliter.

h. Upon the approval of eltenac by the FDA, the maximum permitted plasma concentration of eltenac is 0.1 micrograms per milliliter.

i. Effective April 1, 2010 and through November 30, 2011, at which time only one of the substances listed in (a) through (g) above will be permitted, a maximum of two substances listed in (a) through (g) above are permitted to be present in the same plasma or urine sample, only if both substances are reported on a Federation NSAID Disclosure Form and filed with the competition prior to the horse competing (GR 411 does not apply).

j. Phenylbutazone and flunixin are not permitted to be present in the same plasma or urine sample (GR411 does not apply).

k. Any nonsteroidal anti-inflammatory drug not listed in (a) through (g) above is forbidden to be present in the plasma or urine sample (GR411 does not apply); exception: salicylic acid.

l. Any nonsteroidal anti-inflammatory drug that becomes approved for use in horses can be added to the list of those permitted, after the completion, review and approval of the needed research.

NOTE: You must use a NSAID Disclosure Form to report the use of two NSAIDs; you may not use a USEF Medications Report Form for this purpose.